CLC bio acquires the drug discovery-software company Molegro
Today, CLC bio announced the acquisition of Molegro, a specialized software company focusing on molecular docking, including prediction and analysis of protein-ligand interactions, screening of compound databases for activities against a receptor, and determination of molecule similarity.
The acquisition of Molegro supports CLC bio's strategy of continuously expanding their bioinformatics offerings beyond Next Generation Sequencing, as well as in bioinformatics areas of value to their customer base.
"We have always had a strong focus on the science behind our software, and joining CLC bio allows us to become part of a strong analysis platform and focus even more on developing the next generation of molecular docking products." says CEO at Molegro, René Thomsen, PhD, and continues, "CLC bio has demonstrated the capability to build an elaborate analysis platform and distribute it internationally, and exactly that competence is the best way to take the features of Molegro's software to the next level."
"Since 2005, Molegro has demonstrated the ability to develop and support superior molecular docking products. We look forward to adding the very talented people from Molegro to our team at CLC bio." states CEO at CLC bio, Thomas Knudsen, and adds, "This acquisition underlines our dedication to always look for the most viable ways to enhance our analysis platform for the benefit of our customers."
In the coming years, CLC bio will invest significant resources into the continued development of the acquired protein-ligand docking and data modeling software. All existing Molegro customers with an active support and software upgrade contract have been transferred to CLC bio. Effective immediately, Molegro will become part of CLC bio's organization at their Aarhus, Denmark, headquarters. The financial terms of the transaction were not disclosed.
Published 3 September 2012 by Lasse Goerlitz